Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sham Mailankody

Showing results (1-10 of 174) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2017
Affordable Care Act, Health Insurance Coverage, and Cancer OutcomesSham Mailankody
JAMA|May 19, 2017
Pharmaceutical Marketing for Rare Diseases: Regulating Drug Company Promotion in an Era of Unprecedented AdvertisementSham Mailankody, Vinay Prasad
The Oncologist|July 13, 2016
Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven TherapiesSham Mailankody, Vinay Prasad
Mayo Clinic Proceedings|June 5, 2016
The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is UnbearableVinay Prasad, Sham Mailankody
Blood|October 26, 2013
HIV, EBV, and monoclonal gammopathySham Mailankody, Ola Landgren
JAMA Internal Medicine|September 12, 2017
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After ApprovalVinay Prasad, Sham Mailankody
JAMA|May 6, 2016
Implications of Proposed Medicare Reforms to Counteract High Cancer Drug PricesSham Mailankody, Vinay Prasad
JAMA Oncology|July 17, 2015
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and CostsSham Mailankody, Vinay Prasad
The New England Journal of Medicine|April 18, 2014
Comparative effectiveness questions in oncologySham Mailankody, Vinay Prasad
Blood|August 31, 2015
How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analysesVinay Prasad, Sham Mailankody
Pageof 18

Showing results (1-10 of 174) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2017
Affordable Care Act, Health Insurance Coverage, and Cancer OutcomesSham Mailankody
JAMA|May 19, 2017
Pharmaceutical Marketing for Rare Diseases: Regulating Drug Company Promotion in an Era of Unprecedented AdvertisementSham Mailankody, Vinay Prasad
The Oncologist|July 13, 2016
Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven TherapiesSham Mailankody, Vinay Prasad
Mayo Clinic Proceedings|June 5, 2016
The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is UnbearableVinay Prasad, Sham Mailankody
Blood|October 26, 2013
HIV, EBV, and monoclonal gammopathySham Mailankody, Ola Landgren
JAMA Internal Medicine|September 12, 2017
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After ApprovalVinay Prasad, Sham Mailankody
JAMA|May 6, 2016
Implications of Proposed Medicare Reforms to Counteract High Cancer Drug PricesSham Mailankody, Vinay Prasad
JAMA Oncology|July 17, 2015
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and CostsSham Mailankody, Vinay Prasad
The New England Journal of Medicine|April 18, 2014
Comparative effectiveness questions in oncologySham Mailankody, Vinay Prasad
Blood|August 31, 2015
How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analysesVinay Prasad, Sham Mailankody
Pageof 18